Shares of Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) shot up 6.3% on Wednesday . The stock traded as high as $11.8750 and last traded at $11.8750. 4,164 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 4,529 shares. The stock had previously closed at $11.17.
Telix Pharmaceuticals Price Performance
The business has a 50 day moving average price of $10.06 and a 200-day moving average price of $8.70.
About Telix Pharmaceuticals
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Read More
- Five stocks we like better than Telix Pharmaceuticals
- AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus
- Gold and Silver Recovery—3 Precious Metals Stocks for H2 2026
- Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst
- Why Kroger’s Giant Eagle Deal Could Change Everything
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
